Existing investors of the company, including Longitude Capital, Medicxi and RxCapital , also took part in the round.
A controlled metabolic accelerator (CMA), HU6 can treat cardio-metabolic ailments by addressing obesity, which is a key driver of the diseases.
The CMAS of the company can lower fat throughout the body through mitochondrial uncoupling, a natural process that causes energy regulation.
Rivus previously reported findings from an eight-week Phase IIa metabolic study in obese subjects.
The data established proof of concept that CMAS could potentially treat obesity and various cardio-metabolic ailments, including heart failure with preserved ejection fraction (HFpEF), nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, and type 2 diabetes.
In the trial, HU6 treatment also led to a substantial decline in liver, visceral and total body fat while preserving skeletal muscle mass.
A Phase IIa trial was recently launched that enrolled obese subjects with HFpEF while a Phase IIb trial in obesity, including a subset of obese subjects with type 2 diabetes, is planned to begin next year.
Rivus Pharmaceuticals president and CEO Allen Cunningham said: “We have an exceptional group of investors who share our vision for bringing a new class of treatments to patients with obesity and cardio-metabolic disease.
“Following encouraging data from our Phase IIa clinical trial in patients with obesity, this financing enables us to advance development of HU6 and a pipeline of controlled metabolic accelerators to address a range of cardio-metabolic conditions.”